Key takeaways
Entocort (budesonide) and Remicade (infliximab) are both used to treat Crohn's disease, but they have several differences. Entocort is a corticosteroid taken orally once a day, while Remicade is a biologic disease-modifying antirheumatic drug (DMARD) given through an IV infusion by a healthcare provider. Entocort works by reducing inflammation in the intestines, whereas Remicade blocks a protein called tumor necrosis factor (TNF) to lower inflammation in the body. Entocort is available as a lower-cost generic, and Remicade is available as a lower-cost brand biosimolar. Entocort is typically used for short-term treatment, while Remicade can be used long-term as long as it is effective and well-tolerated. Common side effects of Entocort include headaches and respiratory infections, while Remicade can cause serious infections, cancer, and heart problems. Additionally, Remicade requires regular monitoring and can only be administered by a healthcare professional, whereas Entocort can be taken at home.
